Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VVD-130037
- Development stage
- Phase 1
- Lead developer
- Vividion Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VVD-130037 is an investigational small molecule drug developed by Vividion Therapeutics for the treatment of advanced solid tumors (malignant neoplasms). It acts as a highly specific and potent activator of Kelch-like ECH-associated protein 1 (KEAP1), leading to degradation of nuclear factor erythroid 2–related factor 2 (NRF2). By targeting the KEAP1-NRF2 pathway, which plays a key role in cellular redox homeostasis and cancer cell survival, VVD-130037 aims to disrupt abnormal processes that drive tumor growth. The drug is administered orally and is currently being evaluated in Phase 1 clinical trials for safety, pharmacokinetics/pharmacodynamics, and preliminary efficacy in patients with metastatic or unresectable solid tumors who have progressed after standard therapies[1][3][4][5].
- Other names
- VVD-130037VVD130037VVD 130037BAY3605349BAY-3605349BAY 3605349
02
Targets
KEAP1 (Kelch-like ECH-associated protein 1)
Beyond the preview
Go deeper on VVD-130037.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VVD-130037.